Program Description

This case-based supplement explores managing ocular surface disease across three clinical scenarios: eyelid margin disease and Demodex blepharitis, dry eye disease and inflammation, and ocular toxicity from antibody-drug conjugates in cancer patients, highlighting optometry's evolving diagnostic and treatment role.

Faculty

• Marc Bloomenstein, OD, FAAO
• Mile Brujic, OD, FAAO
• Cecelia Koetting, OD, FAAO, DipABO
• Jacob Lang, OD, FAAO

Learning Objectives

After completing this course, learners will be able to:

• Identify and stage patients with eyelid margin disease (meibomian gland dysfunction [MGD] and Demodex Blepharitis [DB]), tear deficiency, and acute and chronic ocular Inflammation by incorporating consistent examination techniques to recognize the pathognomonic signs.
• Assess traditional and emerging diagnostic methods, including tear osmolarity, MMP-9, anterior segment OCT, meibography/gland expression, collarette detection, and incorporate validated symptom questionnaires and objective clinical data to improve the accuracy of OSD/DED diagnosis.
• Evaluate the various treatment options and apply evidence-based selection criteria to customize management strategies for the latest DB pharmaceuticals, neuromodulation therapies, anti-inflammatories (acute and chronic), mechanical and pharmacological MGD treatments.
• Recognize the ocular findings associated with antibody-drug conjugates (ADCs) for the treatment of certain cancers, perform the appropriate baseline and follow-up ophthalmic exams for patients receiving ADC therapy, and develop effective communication strategies with the patient’s shared care team.

Credit

This enduring educational activity is eligible for 1.0 hour of COPE credit.